The Role of PARP Inhibition in Prostate Cancer: e-Learning Now Available
The Role of PARP Inhibition in Prostate Cancer: e-Learning Now Available
Prof. Emmanuel S. Antonarakis, Dr Neal D. Shore, Prof. Andrew J. Armstrong
The range of therapeutic options in prostate cancer is expanding, including strategies for PARP inhibition.
E-learning |
60 min
|accreditation:
EACCME |
Aug 2020
I agree that this educational programme:
The aim of this e-learning course is to provide an understanding of the mechanism of action of PARP inhibitors; the prevalence of DNA damage repair (DDR) mutations in advanced prostate cancer, as well as approaches for somatic and germline testing to identify patients with these mutations; and the recent and ongoing clinical trial data on PARP inhibition in advanced prostate cancer. Watch this video from Dr. Neal D. Shore and download the educational slides to learn more. Follow the link above to start your e-learning journey today.
This course has been developed by the following expert faculty:
-
Dr. Neal D. Shore, Carolina Urologic Research Center (Myrtle Beach, South Carolina, USA)
-
Prof. Andrew J. Armstrong, Duke University School of Medicine (Durham, North Carolina, USA)
-
Prof. Emmanuel S. Antonarakis, Johns Hopkins Medicine (Baltimore, Maryland, USA)

This course has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) and ECMEC® is available. Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.
Other programmes of interest
Other programmes developed by Dr Neal D. Shore

Dr Neal D. Shore
Urologist
Carolina Urologic Research Centre and GenesisCare
United States (US)